April 25, 2024

• 

[THE INVESTOR] Alteogen said on March 28 that it has signed a contract with Netherlands biotech firm LinXis to exclusively supply its biosimilar referencing Roche’s best-selling monoclonal antibody Herceptin.

Alteogen will provide ALT-02 for the development of antibody drug conjugates, or ADC, which are cytotoxic drugs connected by chemical linkers to monoclonal antibodies that are specific for a tumor-associated antigen, by LinXis.

“By forging the exclusive supply agreement with LinXis, we have established a strategic bridgehead that gives us an upper hand in targeting global breast cancer treatment market,” said Alteogan CEO Park Soon-jae.

Alteogan said the ALT-02 antibody will be used for the Amsterdam-based firm’s HER2-targeting ADC, from preclinical development to final product manufacturing. “But we can’t disclose the deal size nor the volume of the antibody, as the development is still in early stages,” an Altegon official told The Investor.

Alteogen is negotiating with a global pharmaceutical firm to conduct the final phase 3 clinical trials of ALT-02, following completion of phase 1 studies in Canada, it said. The investigational biosimilar was licensed to China’s Qilu Pharmaceutical in March last year.

By Park Han-na (hnpark@heraldcorp.com)